Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial

NCT01799486 is registered in ClinicalTrials.gov with Lin Bingliang as lead sponsor.

NCT NCT01799486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01799486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial
Lead sponsor
Lin Bingliang
Phase
Phase 4
Overall status
Unknown status
Start date
February 28, 2013
Completion date
March 31, 2015
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hbv-related liver cirrhosis